Microbacterium spp. peritonitis in patients undergoing peritoneal dialysis: a single-center experience and literature review

腹膜透析患者微杆菌属腹膜炎:单中心经验及文献综述

阅读:1

Abstract

INTRODUCTION: Peritoneal dialysis-related peritonitis (PDRP) caused by Microbacterium spp. is very rare, with only 9 cases reported to date. In this study, we report the treatment experiences of 7 patients at our peritoneal dialysis center. METHODS: We retrospectively collected clinical characteristics and antibiotic management of all 7 episodes of PDRP caused by Microbacterium spp. in 7 patients from at our center over 4 years, and reviewed the documented Microbacterium spp. PDRP in the literature. RESULTS: Empiric antibiotic therapy was initiated as soon as possible, and consisted of intraperitoneal (IP) gentamicin in combination with vancomycin. After up to 5 days, gentamicin was changed to meropenem if the treatment was not effective. The intended course of antibiotic treatment was 21-day. Totally, 6 episodes were cured (85.7%), which was higher than reported. CONCLUSION: The 21-day antibiotic therapy program by combining vancomycin and meropenem may benefit the management of Microbacterium spp. PDRP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。